ART Advanced Research Technologies to Present SoftScan at the Breast Course Symposium in Quebec City
15 April 2008 - 12:08AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
its participation as a Bronze Sponsor and exhibitor in the 2008
edition of The Breast Course, to be held at the Fairmont Chateau
Frontenac in Quebec City, Canada from April 13 to April 16, 2008.
ART is an exhibitor at the event and will present its SoftScan�
breast imaging device designed to improve the diagnosis and
treatment of breast cancer, at its booth located in the Frontenac
Room of the Fairmont Chateau Frontenac.
The course is a multidisciplinary event aiming to present the
best practices and state-of-the-art products to breast
professionals and brings together an international faculty of
opinion leaders in breast cancer detection, intervention and
therapy offering top-notch instruction to more than 350
participants from 26 countries.
"We are pleased to be present once again this year at The Breast
Course symposium, which is now recognized worldwide as the premier
educational event dealing with breast diseases and which gives us
the opportunity to showcase our SoftScan system to an audience of
breast care specialists and other participants from over 25
countries," said Sebastien Gignac, ART's President and CEO. "The
SoftScan system, now approved for commercialization in Canada and
Europe, offers another option to women and their physicians in
instances where mammography is either ineffective or impractical to
use, as well as the possibility to monitor the treatment of
patients undergoing chemotherapy for breast cancer," he added.
About SoftScan�
The SoftScan� optical breast imaging system has been designed
first as a complementary diagnostic tool to mammography, with
ultimate uses in the detection and treatment monitoring of breast
cancer. Its non-invasive, painless approach uses time-domain
optical imaging technology, which may allow clinicians to better
locate and characterize breast tumors as benign or malignant and
could provide faster assessment of therapeutic effectiveness.
Unlike mammography whose use must be strictly limited, the SoftScan
system emits no radiation and can be safely used as often as needed
to monitor patients. The device was created and developed by ART
Advanced Research Technologies Inc., and has obtained regulatory
approvals for its commercialization in Canada and in Europe.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
these products in a global strategic alliance with GE Healthcare, a
world leader in mammography and imaging. Finally, the Fenestra�
line of molecular imaging contrast products provide image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART's
shares are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca .
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2007, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024